These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12169042)

  • 81. Metabolism of loratadine and further characterization of its in vitro metabolites.
    Ghosal A; Gupta S; Ramanathan R; Yuan Y; Lu X; Su AD; Alvarez N; Zbaida S; Chowdhury SK; Alton KB
    Drug Metab Lett; 2009 Aug; 3(3):162-70. PubMed ID: 19702548
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.
    Potter PC; Kapp A; Maurer M; Guillet G; Jian AM; Hauptmann P; Finlay AY
    Allergy; 2009 Apr; 64(4):596-604. PubMed ID: 19053988
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor.
    Kazmi F; Yerino P; Barbara JE; Parkinson A
    Drug Metab Dispos; 2015 Sep; 43(9):1294-302. PubMed ID: 26135009
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Simultaneous determination of desloratadine and its active metabolite 3-hydroxydesloratadine in human plasma by LC/MS/MS and its application to pharmacokinetics and bioequivalence.
    Xu HR; Li XN; Chen WL; Chu NN
    J Pharm Biomed Anal; 2007 Nov; 45(4):659-66. PubMed ID: 17936534
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment.
    Gupta SK; Kantesaria B; Wang Z
    J Clin Pharmacol; 2007 Oct; 47(10):1283-91. PubMed ID: 17906161
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine.
    Affrime M; Banfield C; Gupta S; Cohen A; Boutros T; Thonoor M; Cayen M
    Clin Pharmacokinet; 2002; 41 Suppl 1():21-8. PubMed ID: 12169043
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Prevalence of Desloratadine Slow-metabolizer Phenotype and Food-dependent Pharmacokinetics of Desloratadine in Healthy Chinese Volunteers.
    Wang T; Zhang K; Li T; He L; Xie H; Jiang X; Wang L
    Clin Drug Investig; 2015 Dec; 35(12):807-13. PubMed ID: 26446005
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cetirizine and loratadine: minimal risk of QT prolongation.
    Prescrire Int; 2010 Feb; 19(105):26-8. PubMed ID: 20455340
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study.
    Solans A; Carbó ML; Peña J; Nadal T; Izquierdo I; Merlos M
    Clin Ther; 2007 May; 29(5):900-908. PubMed ID: 17697908
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety.
    Prenner B; Kim K; Gupta S; Khalilieh S; Kantesaria B; Manitpisitkul P; Lorber R; Wang Z; Lutsky B
    Expert Opin Drug Saf; 2006 Mar; 5(2):211-23. PubMed ID: 16503743
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Chronic Urticaria in Older Adults: Treatment Considerations.
    Patruno C; Fabbrocini G; Cillo F; Torta G; Stingeni L; Napolitano M
    Drugs Aging; 2023 Mar; 40(3):165-177. PubMed ID: 36808569
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).
    Ecevit MC; Özcan M; Haberal Can İ; Çadallı Tatar E; Özer S; Esen E; Atan D; Göde S; Elsürer Ç; Eryılmaz A; Uslu Coşkun B; Yazıcı ZM; Dinç ME; Özdoğan F; Günhan K; Bilal N; Korkut AY; Kasapoğlu F; Türk B; Araz Server E; Önerci Çelebi Ö; Şimşek T; Kum RO; Adalı MK; Eren E; Yüksel Aslıer NG; Bayındır T; Çakır Çetin A; Enise Göker A; Adadan Güvenç I; Köseoğlu S; Soylu Özler G; Şahin E; Şahin Yılmaz A; Güne C; Aksoy Yıldırım G; Öca B; Durmuşoğlu M; Kantekin Y; Özmen S; Orhan Kubat G; Köybaşı Şanal S; Altuntaş EE; Selçuk A; Yazıcı H; Baklacı D; Yaylacı A; Hancı D; Doğan S; Fidan V; Uygur K; Keleş N; Cingi C; Topuz B; Çanakçıoğlu S; Önerci M
    Turk Arch Otorhinolaryngol; 2021 May; 59(Suppl 1):1-157. PubMed ID: 34212158
    [TBL] [Abstract][Full Text] [Related]  

  • 93. In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells.
    Gamperl S; Stefanzl G; Willmann M; Valent P; Hadzijusufovic E
    Vet Med Sci; 2021 Jan; 7(1):57-68. PubMed ID: 32924324
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Brain histamine H
    Nakamura T; Hiraoka K; Harada R; Matsuzawa T; Ishikawa Y; Funaki Y; Yoshikawa T; Tashiro M; Yanai K; Okamura N
    Pharmacol Res Perspect; 2019 Aug; 7(4):e00499. PubMed ID: 31338198
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms.
    Ventura MT; Scichilone N; Paganelli R; Minciullo PL; Patella V; Bonini M; Passalacqua G; Lombardi C; Simioni L; Ridolo E; Del Giacco SR; Gangemi S; Canonica GW
    Clin Mol Allergy; 2017; 15():2. PubMed ID: 28174512
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial.
    Wandalsen GF; Miranda C; Ensina LF; Sano F; Amazonas RB; Silva JMD; Solé D
    Braz J Otorhinolaryngol; 2017; 83(6):633-639. PubMed ID: 27670203
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach.
    Han X; Quinney SK; Wang Z; Zhang P; Duke J; Desta Z; Elmendorf JS; Flockhart DA; Li L
    Clin Pharmacol Ther; 2015 Sep; 98(3):321-7. PubMed ID: 25975815
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Allergic diseases in the elderly.
    Cardona V; Guilarte M; Luengo O; Labrador-Horrillo M; Sala-Cunill A; Garriga T
    Clin Transl Allergy; 2011 Oct; 1(1):11. PubMed ID: 22409889
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2).
    Zolk O; Solbach TF; König J; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Apr; 379(4):337-48. PubMed ID: 19002438
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
    Devillier P; Roche N; Faisy C
    Clin Pharmacokinet; 2008; 47(4):217-30. PubMed ID: 18336052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.